TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00272493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus vaccine with GM-CSF adjuvant
Description: Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B virus vaccine
Description: Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
Study: NCT05953545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda
Description: Study intervention for this protocol includes a weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
Study: NCT05494840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haptonomy
Description: Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Haptonomy
Description: Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
Study: NCT04673318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heat therapy
Description: leg heated garments with circulating water to conduct heat therapy at home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
Study: NCT05247372

Intervention type: OTHER
Group type: OTHER
Intervention: The effect of Iyengar yoga practice on patients with multiple sclerosis
Description: The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
Study: NCT06566118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimülation
Description: Both groups were subjected to exercise loading, then Group 1 was subjected to active auricular VSS, and Group 2 was subjected to sham VSS. The application was made simultaneously from both ears, with a pulse duration of 300 microseconds, a biphasic asymmetric waveform and a frequency of 25 Hz for a total of 20 minutes. All evaluations were recorded 3 times for both groups: at the beginning of the test, after exercise loading, and after active and sham VSS application. As a result of the evaluations made for both groups, comparisons were made between and within the groups.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular Vagus Nerve Stimülation
Description: Both groups were subjected to exercise loading, then Group 1 was subjected to active auricular VSS, and Group 2 was subjected to sham VSS. The application was made simultaneously from both ears, with a pulse duration of 300 microseconds, a biphasic asymmetric waveform and a frequency of 25 Hz for a total of 20 minutes. All evaluations were recorded 3 times for both groups: at the beginning of the test, after exercise loading, and after active and sham VSS application. As a result of the evaluations made for both groups, comparisons were made between and within the groups.
Study: NCT04970563

Intervention type: OTHER
Group type: OTHER
Intervention: Body odor samples
Description: Participants will provide six body odor samples (mask and sweat samples) at inclusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body odor samples
Description: Participants will provide six body odor samples (mask and sweat samples) at inclusion

Intervention type: OTHER
Group type: OTHER
Intervention: Body odor samples
Description: Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
Study: NCT06514157

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)
Description: BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)
Study: NCT06551272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXL01
Description: EXL01 contains an unmodified single strain of F. prausnitzii
Study: NCT05854108

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cervical Traction
Description: Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Snag
Description: Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
Study: NCT05388786

Intervention type: BEHAVIORAL
Intervention: Delphi Questionnaire
Description: An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed.
Study: NCT05179252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shen-Fu injection
Description: Chinese patent medicine made by modern technology

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: 0.9% normal saline, used for sham control
Study: NCT06329908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LG002
Description: Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
Study: NCT04739982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GuessWhat Mobile App
Description: The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
Study: NCT03380728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibogaine Hydrochloride
Description: The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Study: NCT04741581

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: ThickenUp® Gel Express
Description: Thickening gel
Study: NCT05112952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.
Study: NCT05523765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Description: Oral Brepocitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Description: Oral Brepocitinib
Study: NCT06389396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP362 Test Catheter
Description: The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen Plus TAI system.
Study: NCT05553509

Intervention type: OTHER
Intervention: PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY
Description: SURGICAL DEBRIDEMNT

Intervention type: OTHER
Intervention: PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY
Description: SURGICAL DEBRIDEMNT
Study: NCT05405920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-based Care Strategy for Hypertension Control
Description: The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
Study: NCT06179407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
Study: NCT05112952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib tablet will be administered orally.
Study: NCT06138314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Program
Description: The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
Study: NCT06179407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
Study: NCT06547437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Papaverine
Description: papaverine a smooth muscle relaxant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 0.9% 100 cc
Study: NCT05937841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 21
Description: AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response
Study: NCT05830708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus sp. probiotic
Description: The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy
Description: The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
Study: NCT05967598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham cyma conchae stimulation
Description: The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham cyma conchae stimulation
Description: The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
Study: NCT05896228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).
Study: NCT05121766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 (EPA+DHA)
Description: Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 Soybean Oil Placebo capsules
Study: NCT05697627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) using EndeavorRx
Description: The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks
Study: NCT05473988

Intervention type: OTHER
Intervention: Admission to General Ward
Description: Admission to General Ward

Intervention type: OTHER
Intervention: Admission to Intensive Care Unit
Description: Admission to Intensive Care Unit
Study: NCT06138314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization
Description: Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
Study: NCT05473988

Intervention type: OTHER
Intervention: 30 Day Mortality
Description: 30 Day Mortality
Study: NCT05302674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Dry
Description: 98°F (36.7°C) and 20% relative humidity environment
Study: NCT06416566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Enoxaparin
Description: Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
Study: NCT05485740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive multisensory rehabilitation
Description: sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the selected exercise program
Description: Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the selected exercise program
Description: Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
Study: NCT04997499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watch an instructional video
Description: watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
Study: NCT03775460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants in the intervention group will receive methotrexate along side prednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control arm will receive placebo along side prednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks